Momenta Pharmaceuticals Inc Revenue Growth Rates (MNTA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Momenta Pharmaceuticals inc   (NASDAQ: MNTA)
 

MNTA's Revenue Growth by Quarter and Year

Momenta Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MNTA Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September -
2nd Quarter June 6.61
1st Quarter March 8.89
FY 15.50

MNTAs Annual Revenue
Momenta Pharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 23.87 millions
Momenta Pharmaceuticals Inc 's Revenue in the fiscal year 2018 $ 75.59 millions
Momenta Pharmaceuticals Inc 's Revenue in the fiscal year 2017 $ 138.88 millions
Momenta Pharmaceuticals Inc 's Revenue in the fiscal year 2016 $ 109.62 millions
Momenta Pharmaceuticals Inc 's Revenue in the fiscal year 2015 $ 89.65 millions




MNTA Revenue second quarter 2020 Y/Y Growth Comment
Momenta Pharmaceuticals inc achieved in the second quarter 2020, above Company average Revenue growth of 27.61% year on year, to $ 6.61 millions.

Looking into second quarter 2020 results within Biotechnology & Pharmaceuticals industry 24 other companies have achieved higher Revenue growth. While Momenta Pharmaceuticals Inc ' s Revenue rise of 27.61% ranks overall at the positon no. 567 in the second quarter 2020.


MNTA Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - -80.9 % -33.73 % 88.92 %
3rd Quarter September - -57.06 % -38.23 % -17.33 %
2nd Quarter June 27.61 % -60.25 % -44.72 % -10.82 %
1st Quarter March 116.3 % -15.26 % -81.77 % 34.06 %
FY   - -68.43 % -45.58 % -

Financial Statements
Momenta Pharmaceuticals Inc 's second quarter 2020 Revenue $ 6.61 millions MNTA's Income Statement
Momenta Pharmaceuticals Inc 's second quarter 2019 Revenue $ 5.18 millions Quarterly MNTA's Income Statement


MNTA Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - 28.01 % 187.77 % 168.2 %
3rd Quarter September - 23.36 % 14.2 % 2.21 %
2nd Quarter June -25.65 % 26.03 % 168.66 % -11.42 %
1st Quarter March 8.68 % -90.4 % -92.49 % -22.19 %
FY (Year on Year)   - -68.43 % -45.58 % -


Back to MNTA Growth rate Comparisons >> Back to MNTA Growth rate Comparisons >>


Revenue second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #25
Healthcare Sector #144
Overall #567

Revenue Y/Y Growth Statistics
High Average Low
310.05 % 21.08 % -81.77 %
(Jun 30 2015)   (Mar 31 2018)
Revenue second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #25
Healthcare Sector #144
Overall #567
Revenue Y/Y Growth Statistics
High Average Low
310.05 % 21.08 % -81.77 %
(Jun 30 2015)   (Mar 31 2018)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Momenta Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
424.41 % 31.38 % -92.49 %
(Jun 30 2015)  


MNTA's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2020 Momenta Pharmaceuticals Inc disclosed fall in Revenue from the first quarter by -25.65% to $ 6.61 millions, from $ 8.89 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2020 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 47 other companies have achieved higher Revenue quarter on quarter growth. While Momenta Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3179.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #48
Healthcare Sector #465
Overall #3179
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #48
Healthcare Sector #465
Overall #3179
Revenue Q/Q Growth Statistics
High Average Low
424.41 % 31.38 % -92.49 %
(Jun 30 2015)  


MNTA's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2020 Momenta Pharmaceuticals Inc disclosed fall in Revenue from the first quarter by -25.65% to $ 6.61 millions, from $ 8.89 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2020 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 47 other companies have achieved higher Revenue quarter on quarter growth. While Momenta Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3179.


Momenta Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)
Cumulative Revenue 12 Months Ending $ 30.07 $ 28.64 $ 23.87 $ 58.51 $ 67.00
Y / Y Revenue Growth (TTM) -55.12 % -61.73 % -68.42 % -39.91 % -37.14 %
Year on Year Revenue Growth Overall Ranking # 3382 # 3377 # 3650 # 1885 # 2277
Seqeuential Revenue Change (TTM) 4.99 % 20.01 % -59.21 % -12.68 % -10.49 %
Seq. Revenue Growth (TTM) Overall Ranking # 2589 # 139 # 3799 # 3103 # 2487


Cumulative Revenue growth Comment
Momenta Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2020. If the fiscal year would end in Jun 30 2020, Momenta Pharmaceuticals Inc 's annual Revenue decrease would be -55.12% year on year to $30 millions.

In the Healthcare sector 446 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3377 to 3382.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 35
Healthcare Sector # 447
Overall # 3382

Revenue TTM Y/Y Growth Statistics
High Average Low
101.81 %
 7.75 %
-68.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 35
Sector # 359
S&P 500 # 2589
Cumulative Revenue growth Comment
Momenta Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2020. If the fiscal year would end in Jun 30 2020, Momenta Pharmaceuticals Inc 's annual Revenue drop would be -55.12% year on year to $30 millions.

In the Healthcare sector 446 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3377 to 3382.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 35
Healthcare Sector # 447
Overall # 3382

Revenue TTM Y/Y Growth Statistics
High Average Low
101.81 %
7.75 %
-68.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 35
Sector # 359
S&P 500 # 2589




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MNTA's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2020
Adamas Pharmaceuticals Inc48.09%$ 48.089 millions
Biolife Solutions Inc 48.04%$ 48.038 millions
China Pharma Holdings Inc46.75%$ 46.755 millions
Intellia Therapeutics Inc 46.28%$ 46.276 millions
Inotiv Inc 45.15%$ 45.152 millions
Sarepta Therapeutics Inc 45.10%$ 45.100 millions
Q32 Bio Inc 44.64%$ 44.643 millions
Horizon Therapeutics Public Limited Company44.33%$ 44.327 millions
Koru Medical Systems Inc 44.12%$ 44.124 millions
Acceleron Pharma inc43.69%$ 43.685 millions
Collegium Pharmaceutical Inc 43.59%$ 43.593 millions
Arvinas Inc 43.10%$ 43.102 millions
Agios Pharmaceuticals Inc 42.43%$ 42.432 millions
Insmed Inc41.78%$ 41.782 millions
T2 Biosystems Inc 41.46%$ 41.463 millions
Amicus Therapeutics inc 41.29%$ 41.294 millions
Halozyme Therapeutics Inc 41.06%$ 41.057 millions
Ibio inc 40.88%$ 40.881 millions
Misonix Inc 40.59%$ 40.587 millions
Infinity Pharmaceuticals Inc 40.08%$ 40.078 millions
Denali Therapeutics Inc 39.31%$ 39.314 millions
Sorrento Therapeutics Inc 39.06%$ 39.061 millions
Precipio inc 38.85%$ 38.854 millions
Biotricity Inc 38.20%$ 38.195 millions
Morphic Holding inc 38.19%$ 38.189 millions
Dermtech Inc 37.46%$ 37.459 millions
Verastem Inc 37.34%$ 37.341 millions
Collplant Biotechnologies Ltd35.81%$ 35.809 millions
Exact Sciences Corporation34.52%$ 34.521 millions
Dexcom Inc 34.30%$ 34.304 millions


About Momenta Pharmaceuticals Inc Revenue Growth Rates (MNTA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.